Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stanford researcher shows flu shot benefits outweigh costs in healthy young adults

20.08.2002


Flu shots can save lives, especially among the elderly who account for most of the 20,000 flu-related deaths in the United States each year. But physicians have debated whether vaccinating healthy, younger adults is worth the time and money. The answer is yes, according to a new study based on a computer model. The study was led by Patrick Lee, MD, a resident in internal medicine at Stanford Hospital & Clinics.



"There’s been a lot of debate about optimal treatment strategies," Lee said. "Our study shows that society as a whole benefits if you vaccinate the entire population and use antiviral medications on those who get sick."

Influenza, a viral disease characterized by nasal congestion, dry cough and fever, affects 10 percent to 20 percent of the U.S. population each year, with an average of 2.8 work days lost per ill individual. Although anyone can get a flu shot, the Centers for Disease Control recommend vaccination only for specific groups, including the elderly, those with weakened immune systems and health-care workers. Most healthy adults choose not to get flu shots.


In the study, published in the Aug. 20 issue of the journal Annals of Internal Medicine, Lee and colleagues gathered previously published data on the costs and benefits of flu vaccination and treatment of flu patients with antiviral medication in healthy adults ages 18 to 50. These included costs of the vaccine and drugs, lost work time due to illness and duration of symptom relief from antiviral medications. They also surveyed 210 patients at a family practice clinic about their willingness to pay for flu symptom relief and medication without side effects.

The researchers entered this information into a computer model that subtracted the costs from the benefits to yield a net benefit or cost. They ran the model 1,000 times while systematically changing the data within known limits. For example, the cost of the flu vaccine averages $10.41 but may range from $5 to $20. For each combination of costs and benefits, the computer determined which of eight prevention and treatment strategies was most cost beneficial. The strategies included either vaccination or non-vaccination and, for those who became ill, treatment with one of three antiviral medications, including rimantadine, zanamivir and oseltamivir, or no treatment.

Using the average values for all costs and benefits, the researchers found that the four strategies that included vaccination had an overall savings of about $30 each compared to no vaccination and no treatment with antivirals. Treatment with rimantidine or zanamavir without vaccination had small savings (less than $5); treatment with oseltamivir without vaccination had a cost of 3 cents.

Lee said using a computer model may appear less rigorous because randomized clinical trials are usually the gold standard of medical research. But two previous clinical trials on the costs and benefits of flu vaccinations for healthy adults yielded widely different results. One found a savings of $46.85 per vaccination, while another found costs of $65.59 and $11.17 per vaccination over two seasons.

"Clinical trials are snapshots in time. They look at one flu season and one flu vaccine," Lee said. "In a clinical scenario where variables change over time, randomized clinical trials are not the best way to answer questions."

Using their computer model, Lee and colleagues found that a strategy that included vaccination was optimally cost-beneficial in 95 percent of their 1,000 runs. Non-vaccination became optimal when the probability of contracting the flu was less than 6.3 percent - a very mild flu season.

The study also found that treatment of flu patients with antiviral medications was optimal in 85 percent of the runs. Surprisingly, the older antiviral rimantidine was as effective as the newer drugs zanamivir and oseltamivir. But no drug emerged as a clear winner; the medications need to be compared in head-to-head tests, Lee said.

All three antiviral medications are readily available, but the United States has experienced shortages of the flu vaccine in recent years. The prevalence of different flu strains changes over time, so the two main pharmaceutical companies that manufacture the vaccine make new batches each year based on World Health Organization recommendations. In 2001, fewer than 90 million doses were available in the United States, and shipment of the vaccine to clinics was delayed.

"For most flu seasons, it is cost-beneficial for the whole society to be vaccinated. But, if there’s not enough vaccine to go around, you need to vaccinate those who need it most first," Lee said.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>